ACTRN12618001424291已完成1 期
A Phase 1, Randomised, Placebo-controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Healthy Volunteers
Victorian State Government0 个研究点目标入组 24 人开始时间: 2018年8月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 49 Years（—）
- 性别
- All
入选标准
- •1.Male or females aged between 18 - 49 years (inclusive);
- •2.Body mass index between 18 and 30 kg/m2 (inclusive);
- •3.Negative screen for drugs of abuse, alcohol, hepatitis B surface antigen, Hepatitis C Virus and Human Immunodeficiency Virus;
- •4.Negative screen for drugs of abuse and alcohol pre-dose on Day -1;
- •5.Clinical laboratory values within the normal limits as defined by the clinical laboratory, unless the results are deemed as not clinically significant by the investigator
- •6.Be in general good health without clinically significant medical history;
- •7.Ability to provide written informed consent;
- •8.Willing and able to follow study instructions and likely to complete all study requirements;
- •9.Females of childbearing potential must agree to use an established oral, injected or implanted hormonal method of contraception throughout the study (Screening to Day 15) and for 90 days after receiving the study drug.
- •10. Males must agree to use adequate methods of contraception throughout the study (Screening to Day 15) and for 90 days after receiving study drug, excluding sterilized males (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate)
- •11.Suitable venous access.
排除标准
- •1.Positive screening result for cannabis use;
- •2.Current smoker, or a history of regular (more than weekly) use of tobacco- or nicotine-containing products (including e-cigarettes) within 2 months prior to screening; cotinine (nicotine) test to be performed at screening;
- •3.History of excessive alcohol intake (more than four standard drinks daily, on average) or use of recreational drugs within the last 3 months prior to screening;
- •4.Use of prescription or over the counter medications within 7 days of investigational product administration, except for hormonal contraception, simple analgesics such as paracetamol, oral non-steroidal anti-inflammatory drugs and vitamins unless approved by the sponsor medical monitor and study doctor;
- •5.Consumption of grapefruit, grapefruit juice and Seville oranges within 1 week prior to study drug dose or the use of CYP3A inducers/inhibitors within 2 weeks prior to study drug dose, until completion of the study (Day 15 visit). Study doctor will advise what these inducers/inhibitors are..
- •6 Standard donation of blood within 30 days of investigational product administration;
- •7.Participation in any investigational drug study within 30 days prior to screening;
- •8.Females who are pregnant or breastfeeding;
- •9.Clinically significant (as judged by the investigator) presence of acute illness (e.g. gastrointestinal illness, infection such as influenza, upper respiratory tract infection) at admission to the study unit;
- •10.Anticipated need for surgery or hospitalisation during the study;
- •11.History of brady- or tachy-dysrhythmias;
- •12. History of heart failure or heart disease;
- •13. Sensitivity to CBD;
- •14.Allergy to soybeans or any of the excipients in the IP or placebo preparation.
- •15.Any condition, which in the investigator’s opinion, puts the subject at significant risk, could confound the study results or may interfere significantly with the subject’s participation in the study.
研究者
相似试验
已完成
1 期
Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants.CTRI/2021/04/032688Gennova Biopharmaceuticals Limited82
撤回
1 期
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous TIMP-GLIA in Healthy Volunteers.ACTRN12618000459224Delpharm Consultants Pty Ltd48
已完成
1 期
A Phase 1, placebo and positive-controlled, dose-escalation study to determine the safety, pharmacodynamics and pharmacokinetics of a single intravenous injection ofHSK3486 in healthy subjects.AnesthesiaAnaesthesiology - AnaestheticsACTRN12614000428662Sichuan Haisco Pharmaceutical Co., Ltd.48
进行中（未招募）
1 期
Testing eltrombopag in patients with acute myelogenous leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabineAcute myelogenous leukemiaMedDRA version: 18.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2013-000642-20-BEGlaxoSmithKline Research and Development Ltd120
进行中（未招募）
1 期
Testing eltrombopag in patients with acute myelogenous leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabineEUCTR2013-000642-20-PLGlaxoSmithKline Research and Development Ltd120